SOURCE: Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc.

September 02, 2014 09:00 ET

Cleveland BioLabs to Present at Rodman & Renshaw 16th Annual Global Investment Conference

BUFFALO, NY--(Marketwired - Sep 2, 2014) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the Rodman & Renshaw 16th Annual Global Investment Conference, September 8-10, in New York, NY.

Yakov Kogan, Ph.D., MBA Chief Executive Officer and Langdon Miller, M.D., senior medical advisor of Cleveland BioLabs, will present the Company's biodefense and oncology programs on September 10 at 9:10 a.m. ET. A live and archived webcast of the Company's presentation will be available on the investor page of the Cleveland BioLabs website at www.cbiolabs.com.

About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant medical need. The company's lead product candidates are Entolimod, which is being developed as radiation countermeasure and a potential cancer treatment, and Curaxin CBL0137, our lead oncology product candidate. The company conducts business in the United States and in the Russian Federation through our three operating subsidiaries, Incuron, LLC, BioLabs 612, LLC and Panacela Labs, Inc. The company maintains strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, and the Children's Cancer Institute Australia. To learn more about Cleveland BioLabs, Inc., please visit the Company's website at http://www.cbiolabs.com.

Contact Information

  • Contact:
    Rachel Levine
    Vice President, Investor Relations
    Cleveland BioLabs, Inc.
    T: (917) 375-2935
    E: rlevine@cbiolabs.com